Serum Institute

The Competition Commission of India (CCI) has approved a proposed deal involving Serum Institute Life Sciences, Covidshield Technologies and Biocon Biologics. Once the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to the notice filed with the regulator. Covidshield Technologies Pvt Ltd (CTPL), a wholly-owned subsidiary of Serum Institute of Life Sciences, will be merged into Biocon Biologics. In a tweet on Wednesday, the watchdog said it has cleared the "merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for acquisition of approximately 15 per cent equity shareholding of Biocon Biologics by Serum Institute Life Sciences." CTPL was incorporated to undertake the business of marketing, selling and distributing vaccines, drugs and other pharmaceutical products. Biocon Biologics Ltd is a subsidiary of Biocon Ltd. It offers treatment for chronic and acute diseases such as

Serum Institute of India on Friday said it has signed an agreement with the Symbiosis International University earlier this month to set up a research centre for vaccines and biologicals. The R&D (Research & Development) centre will lead the development of new vaccines, technologies, products and innovations in immunisation practices that provide equitable access to life-saving interventions, especially across Low- and Middle-Income Countries (LMICs). The entity will work towards improving health equity against future pandemics and infectious diseases. It will also ensure cross-programme coordination and collaboration, as the facility will be an ecosystem that would also have R&D centres for stem cells, nanotechnology, medical image analysis, applied artificial intelligence and waste resource management, among others. "The research centre will be instrumental in advancing indigenous capabilities for end-to-end development of any futuristic technology and projects in the ...

The decision, which the website attributes to Serum chief Adar Poonwala, comes a day ahead of the start of the programme to keep booster Covid-19 dose open for all adults

150 mn doses of Corbevax, Covovax expected monthly from March

Wakau offers a combination of mobile-first screen experience and short video content in entertainment and fashion domains

The pledge builds on the collaboration between Oxford University, AstraZeneca and SII, the world's largest maker of vaccines

The vaccine, called Covovax, has shown good results in trials in children aged three and older.

Serum Institute of India has urged the government to fast-track Covishield movement citing the difficulties being faced in production and cold chain space planning for other vaccines

British cell therapy firm makes announcement.

Poonawalla said easing the export restrictions is a government of India's decision, and he will go by what the Centre feels is appropriate

Biocon Biologics, a subsidiary of Biocon, on Thursday said it will offer around 15 per cent stake to Serum Institute Life Sciences at a post-money valuation of about $4.9 billion

Serum Institute of India (SII) will start production of Sputnik vaccine at the company's facilities in September, Russian Direct Investment Fund (RDIF) said on Tuesday.

India will allow entry of this vaccine once the USFDA approves it

Serum Institute has disassociated itself from its executive director's statement that govt began the Covid vaccination of multiple age groups without taking into consideration the available stock

Company says it never exported vaccines at the cost of the people of India

India's self-sufficiency in vaccine production was destroyed one and half decades ago under the UPA-I government, by moving vaccine manufacture and government procurement to the private sector

To this, the SII said they are doing their best to meet countrywide vaccine requirements.

Adar Poonawalla said last week that the Serum Institute would be able to raise its monthly output to 100 million doses by July

Free, universal access to inoculation could prepare India better for a third Covid-19 resurgence.

'We have always stood in solidarity with our friends and our partners in India,' says State Department.